Horizon – Intention to float on AIM
Horizon Discovery Group plc Announces Intention to Float THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED… Read More
Cambridge Enterprise
A huge thank you to all the team at Cambridge Enterprise for an excellent University of Cambridge Enterprise Fund investor evening yesterday at Emmanuel College. Investee companies presenting included: Aqdot (highlighted in the FT yesterday) Cambridge CMOS Sensors DefiniGEN… Read More
Horizon Discovery
Appointment of Chairman – Horizon Discovery has appointed Dr. Ian Gilham as Chairman of its Board of Directors. Dr. Gilham’s healthcare industry career spans thirty years encompassing all aspects of successful company growth and development. He was Chief Executive… Read More
Horizon Discovery
Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines Cambridge, UK, 30 January 2014: Horizon Discovery™ (Horizon), a leading provider of research… Read More
Horizon Discovery
Jan 7 (Reuters) – Horizon Discovery: * Horizon discovery and Astrazeneca have entered into a research, collaboration and license agreement * Agreement to explore a range of oncology-relevant genotypes * Will receive an undisclosed upfront payment * Eligible… Read More
DefiniGEN
Parkwalk closes DefiniGEN investment for the University of Cambridge Enterprise Fund II DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology. The Company provides human cells… Read More
Horizon Discovery
Horizon Discovery named in the Deloitte Tech Fast 50 2013
Horizon Discovery
Horizon Discovery: License Agreement agreed for Zinc Finger Nuclease Gene Editing Technology
Horizon Discovery
WSJ – Sigma Licenses CompoZr Zinc Finger Nuclease Technology
AQDOT
Parkwalk closes investment in AQDOT for the University of Cambridge Enterprise Fund I AQDOT‘s technology allows for an energy- and raw material-efficient way of manufacturing microcapsules, leading to lower energy consumption and less waste. Potential applications include encapsulating… Read More
Horizon Discovery
Publication elucidates novel miR-34 tumor suppressor pathway
Horizon Discovery
Secures landmark deal with Hisun Pharmaceuticals A Cambridge UK pioneer in technology that will accelerate development of personalised medicines has secured a multi-million pound landmark deal with a Chinese pharmaceuticals giant….
Sphere Fluidics
Wins ACES award for academic spin-outs University of Cambridge spin-out Sphere Fluidics was among the winners at the ACES awards – the only pan-European awards for academic spin-outs – held earlier this week in Brussels.
AQDOT
Wins RSC Emerging Technologies Competition AQDOT, a spinout company from the Department of Chemistry, has won the first RSC Emerging Technologies Competition for 2013…..
Horizon Discovery
Parkwalk closes investment in Horizon Discovery for the University of Cambridge Enterprise Fund I Horizon’s basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges… Read More
Sphere Fluidics
Parkwalk closes Sphere Fluidics investment for the University of Cambridge Enterprise Fund I Sphere Fluidics has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services. A novel technology platform (called Cyto-MineTM)… Read More
DefiniGEN
Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund I DefiniGEN provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human… Read More
